title: [Adjuvant drug treatment in diabetic patients undergoing percutaneous coronary intervention].
abstract: The authors describe the adjuvant drug treatment during and after percutaneous coronary intervention in order to obtain the reduction of major cardiovascular events, focusing in diabetic patients. In the clinical follow-up of diabetic patients after PCI, special attention to the control measures of cardiovascular risk factors should be observed. Among those measures, a normal glycemic level is fundamental, which can be achieved with usual clinical care. Antiplatelet therapy is a controversy issue until know. Although combined antiplatelet therapy with aspirin and a thienopyridynic is well supported by a number of clinical trials, adding GPIIb/IIIa agents as adjuvants in diabetic patients should not be irrestrictive as suggested by some authors; they should be restricted to patients with a significative thrombotic burden.
authors.affiliation: Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, USP, São Paulo, and Laboratório de Hemodinâmica e Cardiologia Intervencionista, Hospital e Maternidade Celso Pierro-PUC, Campinas, SP, Brazil.
authors.forename: Moysés de Oliveira
authors.initials: Mde O
authors.lastname: Lima Filho
authors.forename: Geraldo Luiz de
authors.initials: GL
authors.lastname: Figueiredo
authors.forename: Jorge Luis
authors.initials: JL
authors.lastname: Haddad
authors.forename: André
authors.initials: A
authors.lastname: Schmidt
authors.forename: Nereida Kilza da Costa
authors.initials: NK
authors.lastname: Lima
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D023903:Coronary Restenosis / Q000209:etiology* / Q000517:prevention & control; D003331:Coronary Vessels / Q000293:injuries; D048909:Diabetes Complications / Q000517:prevention & control; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012307:Risk Factors; D015607:Stents
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D001241:Aspirin